相关实验视频
Updated: Jan 8, 2026

10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
3.9K
针对Cε2表位体的Fabs分解IgE受体复合体,并抑制过敏反应
Hexing Wang1, Tomoaki Ando2, Toshiaki Maruyama3
1Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Science of Allergy and Inflammation, Juntendo University Graduate School of Medicine, Tokyo, Japan.
The Journal of allergy and clinical immunology
|December 14, 2025
概括
针对免疫球蛋白E (IgE) 的Cε2域的抗体片段破坏IgE受体相互作用,为过敏疾病的新抗IgE疗法提供了潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏研究 研究过敏
- 开发治疗性抗体 开发治疗性抗体
背景情况:
- 免疫球蛋白E (IgE) 是过敏反应的核心.
- 独特的IgE Cε2域稳定其与高亲和感受体FcεRI的相互作用.
- 针对人类IgE Cε2域的治疗潜力在很大程度上仍未被探索.
研究的目的:
- 研究针对IgE Cε2域的片段抗原结合 (Fab) 片段对IgE受体相互作用的影响.
- 评估Cε2-向抗体在过敏反应中的治疗潜力.
主要方法:
- 通过子免疫和菌体显示,生成Fab图书馆来对抗人类IgE Cε2-4 .
- 对Fab克隆进行竞争的选,并从FcεRI相互作用中去除IgE.
- 在体外和体内评估Fab克隆对IgE-FcεRI和IgE-CD23相互作用和过敏反应的疗效.
主要成果:
- 反Cε2 Fab片段对IgE-FcεRI复合体表现出破坏性活性,与竞争性抑制相关.
- 强大的Fab克隆有效地将IgE从巨细胞中去除,抑制了体外和体内即时的过敏反应.
- 受到有效Fabs的尾位位于Cε2域的第五个β-sheet和螺旋区域附近.
结论:
- 人类IgE Cε2域在稳定IgE受体复合体方面发挥着至关重要的作用.
- Cε2域代表了开发针对过敏疾病的新型抗IgE疗法的有希望的目标.
相关概念视频
Antibody Structure
65.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.2K
Allergic Reactions
31.9K
Overview
31.9K
Cross-reactivity
32.8K
Overview
32.8K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
Antigens Involved in Adaptive Immunity
1.2K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
Complete Antigens
Complete antigens possess both immunogenicity and...
1.2K

